ALSO NOTED: Galapagos gains development grants;Aastrom to sell stock; and much more...

> Galapagos has garnered €5.2 million in grant money to continue its drug development work. Release

> Aastrom Biosciences is raises $13.5 million in a stock offering. Release

> Chutes & Ladders: Fresh from raising $35 million from a Series B of venture capital, Metastatix has named Carol Gallagher as its new president and CEO. Release (.pdf)

> BioSynthema has inked a deal to use Covidien technology to develop a new, targeted radionuclide therapy product. Release

> Boston Scientific is poised to join its healthcare colleagues in laying off thousands of workers. Report

> Last week, the buzz about GlaxoSmithKline's CEO-presumptive Andrew Witty included worries that his internal competitors for the top slot would jump ship. Now Glaxo may sweeten the pot for those also-rans--by putting them on the board of directors. Report

> Here's Exhibit Z in the long list of reasons why Big Pharma wants to make deals with biotech--and why speculation about Biogen and Genzyme is running so high. Roche and Genentech are both reaping a big harvest from their joint cancer drugs this quarter. Report

> Low doses of a human antibody in mice were effective in repairing damaged myelin, a protective shield for nerves that is destroyed by multiple sclerosis. Report

And Finally... Who is most likely to buy Biogen Idec? Poll